Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Paolo
Apr 16, 2024, 01:48 |
Drugs
Paolo Ciracì: Liquid biopsy to guide adjuvant treatment choice in CRC
Paolo Ciracì, Oncology Resident at University Hospital of Pisa, shared on X/Twitter: "Liquid biopsy to…
Apr 16, 2024, 00:17 |
Blog
Paolo Tarantino: We review best practices and future perspectives for the identification of patients with HER2-low Breast Cancer
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn: "In our latest…
Apr 14, 2024, 13:47 |
Insight
Paolo Tarantino: Do patients with these small triple-negative tumors benefit from chemotherapy?
Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, shared a post on LinkedIn: "One third of…
Apr 11, 2024, 13:38 |
Blog
Paolo Tarantino: Wonderful and fun discussions on ADCs at AACR24 with Helena Yu and Petros Grivas
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared a…
Apr 11, 2024, 12:21 |
Blog
Paolo Tarantino: Easier to get a ticket for a Taylor Swift concert than to find a seat at the AACR24 Next Generation ADC session!
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared…
Apr 10, 2024, 05:00 |
Blog
Paolo Tarantino: Our study on the prognosis of small TNBCs is out in NPJ Journals
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Our study…
Apr 8, 2024, 15:49 |
Insight
Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, recently shared on X: "The TRAIN3…
Apr 8, 2024, 15:17 |
Blog
Petros Grivas: Can’t wait to join Paolo Tarantino and Helena Yu to review ADCs across solid tumors
Petros Grivas, Associate Professor at the University of Washington, recently shared a post by Paolo…
Apr 8, 2024, 03:54 |
Drugs
Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared…
Apr 2, 2024, 05:37 |
Drugs
Paolo Tarantino: The OXEL trial is out on Nature Communications
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…
8
9
10
11
12
All:
264
Posts:
91 - 100
Peyo the Therapy Horse: Comforting Terminally Ill Patients Through Horse Therapy.
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 3
Small Bowel Cancer: Symptoms & Causes, Types, Diagnosis and Treatment
Mikkael A. Sekeres, Candidate for Secretary of ASH
Paolo Tarantino: Top 10 Breast Cancer abstracts from ESMO2024
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube